Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00410
|
|||||
| Drug Name |
Lovastatin
|
|||||
| Synonyms |
2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone; 6 Methylcompactin; 6 alpha-Methylcompactin; 6-Methylcompactin; 6-alpha-Methylcompactin; 6alpha-Methylcompactin; Advicor (TN); Altocor; Altocor (TN); Altoprev; Altoprev (TN); Artein; Belvas; Cholestra; Closterol; Colevix; Hipolip; Hipovastin; L-154803; Lestatin; Lipdip; Lipivas; Lipofren; Liposcler; Lovalip; Lovalord; Lovastatin & Primycin; Lovastatin (USP/INN); Lovastatin [USAN:BAN:INN]; Lovastatin, (1 alpha(S*))-Isomer; Lovastatin, 1 alpha-Isomer (without R*/S* notation); Lovastatina; Lovastatina [Spanish]; Lovastatine; Lovastatine [French]; Lovastatinum; Lovastatinum [Latin]; Lovasterol; Lovastin; Lozutin; MK 803; MK-803; MK803; ML-530B; MSD 803; Mevacor; Mevacor (TN); Mevinacor; Mevinolin; Mevinolin from Aspergillus sp.; Mevlor; Monacolin K; Monakolin K; Nergadan; Paschol; Rextat; Rodatin; Rovacor; Sivlor;Taucor; Statosan (TN); Tecnolip; Teroltrat
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Hypercholesterolemia [ICD11:5C80.0] | Approved | [1] | |||
| Therapeutic Class |
Anticholesteremic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C24H36O5
|
|||||
| Canonical SMILES |
CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C
|
|||||
| InChI |
InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1
|
|||||
| InChIKey |
PCZOHLXUXFIOCF-BXMDZJJMSA-N
|
|||||
| CAS Number |
CAS 75330-75-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 404.5 | Topological Polar Surface Area | 72.8 | ||
| Heavy Atom Count | 29 | Rotatable Bond Count | 7 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
4.3
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321765
,10852021
,11336207
,11361446
,11372945
,11462418
,11466544
,11467664
,11486128
,11491688
,11528634
,12012664
,12146073
,14806053
,14879393
,17389841
,22395934
,24896706
,25622285
,26612569
,26680612
,26697338
,26751557
,26759065
,34717349
,46391668
,46508223
,47515402
,47589078
,47662390
,47662391
,47662392
,47736583
,47959858
,47959859
,48035229
,48185079
,48334593
,48413948
,48416187
,496591
,623233
,7734777
,7847425
,7885508
,7979813
,8150103
,8182985
,855905
,9285
|
|||||
| ChEBI ID |
ChEBI:40303
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Lovastatin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. | |||||
| 3 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.